GSK’s Blenrep Combination Gains the NMPA’s Breakthrough Therapy Designation to Treat R/R Multiple Myeloma
Shots:
- The NMPA has granted BTD to the combination of Blenrep (belantamab mafodotin) and bortezomib + dexamethasone (BorDex) for treating r/r multiple myeloma, supported by the P-III (DREAMM-7) study
- The P-III head-to-head (DREAMM-7) study assessing the safety & efficacy of Blenrep (2.5mg/kg, IV, Q3W) + BorDex vs daratumumab + BorDex to treat r/r MM patients (n=494) treated with at least 1L of therapy
- Study reached its 1EP, showing improved PFS; an OS trend was established during interim analysis which was insignificant, though its evaluation continues. All 2EPs were also improved incl. deeper and more durable responses
Ref: GSK | Image: GSK
Related News:- GSK Reports the EMA’s Acceptance of MAA for Blenrep Combinations to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
